Company news

Precigen, Inc. news in 2019

Precigen, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN-4001 for Treatment of Heart Failure at American Heart Association Annual Meeting

November 17, 2019

Intrexon Reports Third Quarter 2019 Financial Results

November 11, 2019

Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

November 6, 2019

Intrexon to Announce Third Quarter Financial Results on November 12th

November 3, 2019

ActoBio Therapeutics(TM) Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten

August 18, 2019

Intrexon Reports Second Quarter and First Half 2019 Financial Results

August 7, 2019

Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T(TM) in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

August 4, 2019

Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th

July 31, 2019

ActoBio Therapeutics(TM) Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes

June 30, 2019

Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T(TM) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)

June 25, 2019

Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production

June 17, 2019

Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference

June 12, 2019

Intrexon to Participate in 2019 BIO International Convention

May 27, 2019

Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

May 12, 2019

Intrexon to Release First Quarter 2019 Financial Results on May 9th

May 1, 2019

Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting

April 28, 2019

Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland

April 24, 2019

Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper

April 15, 2019

Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference

April 9, 2019

Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management

April 2, 2019

Decks in 2019